Lowering carb intake could help reduce breast cancer risk

Share this content:

the ONA take:

Researchers examining the links between diabetes, obesity, and cancer risk focusing specifically on two factors: IGF-1 receptor status and carbohydrate intake. These factors were examined to determine the validity of  a theory linking insulin activation with breast cancer. Past research implies that over activation of insulin may play a role in poor outcomes for breast cancer survivors, due to the over-activation stimulating the availability of IGF-1 in the blood. Because diet can influence insulin activation, the researchers considered the role of diet and its possible impact on breast cancer prognosis based on expression of the IGF1 receptor in the primary breast tumor tissue.

The research was conducted at Geisel School of Medicine at Dartmouth College over a six-year period. The women studied belonged to a larger intervention trial, the WHEL Study, conducted from 2001 through 2007. The analysis revealed that a lower carbohydrate intake was indeed associated with decreased breast cancer recurrence for the women in the study group. This suggests possible treatments in which an oncologist might tailor a diet for a breast cancer patients based on the primary tumor's molecular characteristics. For now, the researchers espouse the diet pattern suggested by both the American Cancer Association and American Association for Cancer Research, which is a fiber-rich diet comprised of high vegetable and legume intake coupled with lowered intake of refined grains and sugar.

Lowering carb intake could help reduce breast cancer risk
Lowering carb intake could help reduce breast cancer risk
Concerned about the associations between obesity, diabetes, and cancer risk, researchers have looked at one type of breast cancer with women whose tumor tissue is positive for an IGF-1 (insulin-like growth factor 1) receptor. The study has examined the combined association of two factors implicated in tumor growth: carbohydrate intake and IGF1 receptor status.
READ FULL ARTICLE From Digital Journal
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs